L
Lingtai Biopharmaceuticals
Innovative drug discovery advancing precision protein degradation for autoimmunity and oncology
About Lingtai Biopharmaceuticals
Leadingtac is a biotechnology company focused on the discovery and development of innovative drugs, particularly in the field of targeted protein degradation (TPD). The company operates in the biopharmaceutical market, serving clients in the healthcare and pharmaceutical sectors. Leadingtac's business model revolves around developing novel drug candidates that address unmet medical needs in areas such as autoimmunity and oncology. The company generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other biotech and pharmaceutical companies. Leadingtac's management team comprises experienced professionals from Chinese, American, and European biotech and pharmaceutical industries, bringing a wealth of expertise to the company's operations. The company has been recognized for its innovation, being selected as one of KPMG China's 2nd Biotechnology Innovation 50 Companies. Leadingtac is currently advancing its first protein degrader toward clinical trial applications in China, the U.S., and Australia, with a focus on transforming patients' lives through precision medicine.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 23.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Precision Medicine, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2024 | $14M | $55M | Tianrui Fengnian Investment · Zhang Ke Lingyi · Longpan Investment | ↗ |
| SEEDEquity / VC | Nov 2021 | $0 | — | Yuansheng BioVenture | ↗ |
Growth signals
Latest recorded traffic for Lingtai Biopharmaceuticals is 150 monthly website visits, down 87.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lingtai Biopharmaceuticals in the Huangpu ecosystem
The Lingtai Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Yuansheng BioVenture
Series A3 investors entered at this stage
- LILongpan Investment
- TITianrui Fengnian Investment
Zhang Ke Lingyi
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lingtai Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lingtai Biopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









